These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16320417)

  • 21. [Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer].
    Lehr HA; Schaefer SC; Delaloye JF
    Rev Med Suisse; 2009 Jul; 5(211):1525-9. PubMed ID: 19694364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Targeted therapy and breast cancer: state of the art].
    Molnar-Stanciu D; Guimas V; Bensalem A; Thiery-Vuillemin A
    Pathol Biol (Paris); 2012 Aug; 60(4):254-63. PubMed ID: 22728007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trastuzumab in the treatment of breast cancer.
    Hortobagyi GN
    N Engl J Med; 2005 Oct; 353(16):1734-6. PubMed ID: 16236745
    [No Abstract]   [Full Text] [Related]  

  • 24. [Monoclonal antibodies as adjuvant breast cancer therapy. Tumor cells in continuing sleep?].
    MMW Fortschr Med; 2001 Nov; 143(44):56. PubMed ID: 11732401
    [No Abstract]   [Full Text] [Related]  

  • 25. Trastuzumab in breast cancer.
    Gounaris IG
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470950
    [No Abstract]   [Full Text] [Related]  

  • 26. Trastuzumab in breast cancer.
    Gilbert SG
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16467555
    [No Abstract]   [Full Text] [Related]  

  • 27. Targeting progress: the development of growth factor receptor-directed therapy.
    Hortobagyi GN; Khayat D
    Semin Oncol; 2000 Oct; 27(5 Suppl 9):1-2. PubMed ID: 11049050
    [No Abstract]   [Full Text] [Related]  

  • 28. Unusual problems in breast cancer and a rare lung cancer case. Case 1. Clinical complete response of breast cancer metastases after trastuzumab-based immunotherapy.
    Tonini G; Vincenzi B; Santini D; Avvisati G; La Cesa A; Baldi A
    J Clin Oncol; 2003 Jun; 21(11):2215-6. PubMed ID: 12775749
    [No Abstract]   [Full Text] [Related]  

  • 29. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 30. [New development in the treatment of breast cancer. II. Future anti-HER2 therapy].
    Yamashita T; Iwata K
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2551-4. PubMed ID: 20104676
    [No Abstract]   [Full Text] [Related]  

  • 31. Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.
    Ferretti G; Fabi A; Felici A; Papaldo P
    J Clin Oncol; 2010 Jul; 28(20):e337; author reply e338-9. PubMed ID: 20479395
    [No Abstract]   [Full Text] [Related]  

  • 32. HER-2-targeted therapy: lessons learned and future directions.
    Nahta R; Esteva FJ
    Clin Cancer Res; 2003 Nov; 9(14):5078-84. PubMed ID: 14613984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First MAb approved for treatment of metastatic breast cancer.
    Brenner TL; Adams VR
    J Am Pharm Assoc (Wash); 1999; 39(2):236-8. PubMed ID: 10079656
    [No Abstract]   [Full Text] [Related]  

  • 34. Dramatic benefit seen in new cancer treatment. Herceptin plus chemo shows greatest gains compared to any other regimens; may eliminate need for mastectomy.
    Health News; 2005 Nov; 11(11):8-9. PubMed ID: 16294429
    [No Abstract]   [Full Text] [Related]  

  • 35. Breast cancer (metastatic).
    Stebbing J; Glassman R
    Clin Evid; 2004 Jun; (11):2266-99. PubMed ID: 15652111
    [No Abstract]   [Full Text] [Related]  

  • 36. Neutrophil elastase predicts trastuzumab responsiveness in metastatic breast cancer.
    Yamashita J; Akizuki M; Jotsuka T; Harao M; Nakano S
    Breast J; 2006; 12(3):288. PubMed ID: 16684339
    [No Abstract]   [Full Text] [Related]  

  • 37. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
    Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
    Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Herceptin.
    Peyrot J
    Oncol Nurs Forum; 1999 Apr; 26(3):515-6. PubMed ID: 10214591
    [No Abstract]   [Full Text] [Related]  

  • 39. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Individualization of neoadjuvant therapy for breast cancer according to molecular tumor characteristics.
    Hennessy BT; Gonzalez-Angulo AM; Hortobagyi GN
    Nat Clin Pract Oncol; 2005 Dec; 2(12):598-9. PubMed ID: 16341096
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.